Most Important GLP-1 Studies (2023–2026): Evidence Behind Ozempic, Wegovy and New Weight-Loss Drugs
Introduction In recent years, GLP-1 receptor agonists have emerged as one of the most important breakthroughs in modern metabolic medicine. Originally developed to treat type 2 diabetes, these medications are now widely used for weight loss, cardiovascular risk reduction, and metabolic disease management . Drugs such as Ozempic, Wegovy, and Mounjaro have rapidly gained global attention for their ability to produce significant and sustained weight loss while improving multiple cardiometabolic risk factors. GLP-1 (glucagon-like peptide-1) is a natural hormone released from the gut after eating. It plays a key role in regulating blood sugar, appetite, and digestion. By mimicking or enhancing this hormone’s activity, GLP-1 drugs help reduce hunger, slow gastric emptying, improve insulin secretion, and support healthier glucose control. Over the past decade, large randomized clinical trials have demonstrated that these medications can lead to 10–20% reductions in body weight , alongside me...